LSA
CLDX icon

Leonteq Securities AG’s Celldex Therapeutics CLDX Stock Holding History

Leonteq Securities AG’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-500
Closed -$17K – 1211
2023
Q2 		$17K Hold
500
– – ﹤0.01% 976
2023
Q1 		$18K Hold
500
– – ﹤0.01% 938
2022
Q4 		$22.3K Hold
500
– – ﹤0.01% 952
2022
Q3 		$14.1K Hold
500
– – ﹤0.01% 1007
2022
Q2 		$13.5K Hold
500
– – ﹤0.01% 1045
2022
Q1 		$17K Hold
500
– – ﹤0.01% 1024
2021
Q4 		$19.3K Buy
+500
New +$21.8K ﹤0.01% 1048

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Leonteq Securities AG's CLDX Position: Q3 2023 in Review

Leonteq Securities AG sold out of Celldex Therapeutics (CLDX) in Q3 2023, closing a stake of 500 shares — an estimated $17K sold.

Leonteq Securities AG first reported a position in CLDX in Q4 2021 and held it in 7 quarters. The position peaked at $22.3K in Q4 2022. 144 funds tracked by Wall St. Rank hold CLDX as of Q3 2023.

  • Leonteq Securities AG reported no remaining Celldex Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Leonteq Securities AG sold 500 Celldex Therapeutics shares in Q3 2023, an estimated $17K.
  • Leonteq Securities AG first reported a position in Celldex Therapeutics in Q4 2021 and held it in 7 quarters.
  • Leonteq Securities AG's Celldex Therapeutics position peaked at $22.3K in Q4 2022.
  • 144 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2023.

Based on Leonteq Securities AG's 13F filing for Q3 2023, filed 11 Mar 2026.